Report overview
The global Kidney Fibrosis Drugs market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Angiotensin Converting Enzyme (ACE) Inhibitors Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Kidney Fibrosis Drugs include Merck and Co, Galectin Therapeutics, Pfizer Inc, InterMune Inc, La Jolla Pharmaceutical Company, BioLine Rx, F. Hoffman-La Roche, ProMetic Life-Sciences Inc and Genzyme Corporation, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
This report aims to provide a comprehensive presentation of the global market for Kidney Fibrosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Fibrosis Drugs. This report contains market size and forecasts of Kidney Fibrosis Drugs in global, including the following market information:
Global Kidney Fibrosis Drugs Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global Kidney Fibrosis Drugs Market Sales, 2019-2024, 2025-2030, (K Units)
Global top five Kidney Fibrosis Drugs companies in 2023 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Kidney Fibrosis Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Fibrosis Drugs Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Kidney Fibrosis Drugs Market Segment Percentages, by Type, 2023 (%)
Angiotensin Converting Enzyme (ACE) Inhibitors
Pirfenidone
Renin Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Vasopeptidase Inhibitors
Global Kidney Fibrosis Drugs Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Kidney Fibrosis Drugs Market Segment Percentages, by Application, 2023 (%)
Chronic Kidney Diseases
Kidney Cancer Treatment
Others
Global Kidney Fibrosis Drugs Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Kidney Fibrosis Drugs Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Kidney Fibrosis Drugs revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies Kidney Fibrosis Drugs revenues share in global market, 2023 (%)
Key companies Kidney Fibrosis Drugs sales in global market, 2019-2024 (Estimated), (K Units)
Key companies Kidney Fibrosis Drugs sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck and Co
Galectin Therapeutics
Pfizer Inc
InterMune Inc
La Jolla Pharmaceutical Company
BioLine Rx
F. Hoffman-La Roche
ProMetic Life-Sciences Inc
Genzyme Corporation
Outline of Major Chapters:
Chapter 1: Introduces the definition of Kidney Fibrosis Drugs, market overview.
Chapter 2: Global Kidney Fibrosis Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Kidney Fibrosis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Kidney Fibrosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Kidney Fibrosis Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
